Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): A multicentre, phase 2, non-comparative, open-label, randomised trial

The Lancet Infectious Diseases

Volumn 14, Issue 6, 2014, Pages 459-467

  Grinsztejn, Beatriz ^a   De Castro, Nathalie ^b   Arnold, Vincent ^c   Veloso, Valdiléa G ^a   Morgado, Mariza ^d   Pilotto, José Henrique ^e   Brites, Carlos ^f   Madruga, José Valdez ^g   Barcellos, Nêmora Tregnago ^h   Santos, Breno Riegel ⁱ   Vorsatz, Carla ^a   Fagard, Catherine ^c   Santini Oliveira, Marilia ^a   Patey, Olivier ^j   Delaugerre, Constance ^a   Chêne, Geneviève ^c,k   Molina, Jean Michel ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e HOSPITAL GERAL DE FORTALEZA   (Brazil)

^f FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^g Centro de Referencia e Treinamento DST/AIDS   (Brazil)

^h Hosp Sanat Partenon   (Brazil)

ⁱ HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

^j Serviço de Infectologia Hospital Nossa Senhora da Conceição ^*  (France)

^k BORDEAUX UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; EFAVIRENZ; ETHAMBUTOL; GLUCOSE; HEMOGLOBIN; ISONIAZID; LAMIVUDINE; PYRAZINAMIDE; RALTEGRAVIR; RIFAMPICIN; STREPTOMYCIN; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HEMOGLOBIN BLOOD LEVEL; HEPATOBILIARY DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOPATHOLOGY; INFECTION; INTENTION TO TREAT ANALYSIS; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MENINGITIS; MIXED INFECTION; MYCOBACTERIOSIS; NEUTROPHIL COUNT; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SELF REPORT; SEPTIC SHOCK; SIDE EFFECT; SKIN DISEASE; THROMBOCYTE COUNT; TREATMENT DURATION; VIRUS LOAD;

ADENINE; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; BENZOXAZINES; BRAZIL; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PYRROLIDINONES; RNA, VIRAL; TREATMENT OUTCOME; TUBERCULOSIS; VIRAL LOAD;

EID: 84901013920     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70711-X     Document Type: Article

References (23)

1. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011, 365:1492-1501.
2. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011, 365:1471-1481.
3. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011, 365:1482-1491.
4. Ahmad Khan F, Minion J, Al-Motairi A, Benedetti A, Harries AD, Menzies D An updated systematic reviewand meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin Infect Dis 2012, 55:1154-1163.
5. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 2010, 10:489-498.
6. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011, 365:493-505.
7. HIV/AIDS Programme. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection WHO, (accessed July 27, 2013). http://www.who.int/hiv/en/.
8. Scourfield A, Zheng J, Chinthapalli S, et al. Discontinuation of atripla as first-line therapy in HIV-1 infected individuals. AIDS 2012, 26:1399-1401.
9. Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicenter observational study. Lancet Infect Dis 2011, 11:750-759.
10. Ford N, Mofenson L, Kranzer K, et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS 2010, 24:1461-1470.
11. Sibiude J, Mandelbrot L, Blanche S, et al. Birth defect and ART in the French perinatal cohort, a prospective exhaustive study among 13,124 live births from 1994 to 2010. Conference on Retroviruses and Opportunistic Infections, Atlanta, GA USA; March 3-6 2013. Abstract 81.
12. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomized controlled trial. Lancet 2009, 374:796-806.
13. Rockstroh JK, Dejesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr 2013, 63:77-85.
14. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009, 53:2852-2856.
15. Burger DM, Magis-Escurra C, Van der Berk GE, Gelink LB Pharmacokinetics of double-dose raltegravir in two patients with HIV infection and tuberculosis. AIDS 2010, 24:328-330.
16. Mena A, Vazquez P, Castro A, et al. Clinical experience of raltegravir-containing regimens in HIV-infected patients during rifampicin-containing treatment of tuberculosis. J Antimicrob Chemother 2011, 66:951-952.
17. Gervasoni C, Riva A, Impagnatiello C, et al. Is chewed raltegravir an option to care for HIV-infected patients with active tuberculosis?. Clin Infect Dis 2013, 57:480-481.
18. Tuberculosis care with TB-HIV co-management. Integrated management of adolescent and adult illness WHO, (accessed Feb 22, 2014). http://www.who.int/hiv/pub/imai/TB_HIVModule23.05.07.pdf.
19. 2008 ANRS scale to grade the severity of adverse events Agence Française de Recherche sur le SIDA et les Hépatites Virales, (accessed July 27, 2013). http://www.anrs.fr/rubriques-transversales/outils-pour-la-recherche.
20. Meintjes G, Lawn SD, SCano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008, 8:516-523.
21. Bonnet M, Bhatt N, Baudin E, et al. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infect Dis 2013, 13:303-312.
22. A'Hern RP Sample size for exact single-stage phase II designs. Stat Med 2001, 20:859-866.
23. Sauvageon H, Grinsztejn B, Arnold V, et al. Pharmacokinetics of two doses of raltegravir in combination with rifampin in HIV-TB co-infected patients. Results of the ANRS 12 180 Reflate TB sub-study. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, USA: March 3-6, 2013. Abstract 539.